AVLN Earnings Date: Nov 11, 2026 (Estimated) — Avalyn Pharma Inc. Common Stock
NASDAQ
Updated
When is AVLN's next earnings date?
Avalyn Pharma Inc. Common Stock (AVLN) is expected to report Q3 2026 earnings on Wednesday, November 11, 2026 at 6:18 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.71.
How did AVLN do in its last earnings report?
In its most recent report on Aug 12, 2026 (Q2 2026), Avalyn Pharma Inc. Common Stock posted EPS of -$0.98 versus the -$0.78 estimate, a miss of 48.5%. Revenue was $0. The stock's 1-day post-earnings move was +5.4%.
How much does AVLN stock move after earnings?
AVLN beat EPS estimates in 0 of its last 2 reported quarters. Over the last 2 reports the stock moved an average of 4.0% (up or down) in the day after earnings.
About Avalyn Pharma Inc. Common Stock
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-12 | Q2 2026 | -0.78 | -0.98 | -48.48% | $0 | ❌ Miss | +5.41% | +9.59% | -2.23% |
| 2026-06-03 | Q1 2026 | -16.38 | -21.83 | -33.27% | $0 | ❌ Miss | +2.64% | +11.47% | +15.59% |
Showing last 2 quarters.